Davy Figueroa
Hospitalist · Lancaster, CANPI 1780794735
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,174 and has fallen 60.1% since, to $1,267 in 2025. Among hospitalist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $88.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Gilead$2K
- GSK$968
- AbbVie$929
- Novo Nordisk$805
- Johnson & Johnson$707
- plus $4K from 23 others
What the payments were for
- Food & beverage$11,642100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $2,124 |
| Gilead | 16 | $1,620 |
| GSK | 8 | $968 |
| AbbVie(2 entities) | 9 | $929 |
| Novo Nordisk | 7 | $805 |
| Johnson & Johnson | 7 | $707 |
| Amgen | 5 | $614 |
| Lilly USA, LLC | 7 | $541 |
| Teva Pharmaceuticals USA, Inc. | 4 | $488 |
| Boehringer Ingelheim | 4 | $461 |
| Phathom Pharmaceuticals, Inc. | 2 | $253 |
| Paratek Pharmaceuticals, Inc. | 2 | $226 |
| Optinose US, Inc. | 2 | $214 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $166 |
| E.r. Squibb & Sons, L.L.C. | 1 | $142 |
| Bayer | 2 | $135 |
| Madrigal Pharmaceuticals | 1 | $134 |
| Novartis | 1 | $125 |
| La Jolla Pharmaceutical Company | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 1 | $125 |
| Shionogi Inc | 1 | $124 |
| Merck | 1 | $101 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $100 |
| Sunovion Pharmaceuticals Inc. | 1 | $96 |
| Lantheus Medical Imaging, Inc. | 1 | $96 |
| Smith+Nephew | 1 | $95 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $90 |
| Pfizer | 1 | $19 |
| Mylan Specialty L.p. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,642 in reported general payments places this provider in the 95th percentile of 2,469 hospitalist providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 17 | $12,028 |
| ErtapenemErtapenem Sodium | 12 | $10,357 |
| FarxigaDapagliflozin Propanediol | 12 | $7,164 |
| EliquisApixaban | 12 | $6,614 |
| JanuviaSitagliptin Phosphate | 11 | $6,074 |
| Cefepime Hcl | 18 | $5,047 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 15 | $4,859 |
| CeftriaxoneCeftriaxone Sodium | 13 | $3,015 |
| Sucralfate | 13 | $2,645 |
| Vancomycin Hcl | 19 | $2,529 |
| Sodium Chloride0.9 % Sodium Chloride | 20 | $1,217 |
| Cefdinir | 55 | $409 |
| Potassium Chloride | 37 | $301 |
| Metoprolol Succinate | 45 | $257 |
| Pantoprazole Sodium | 18 | $164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $125 | $12,02817 claims |
| AstraZenecaFarxiga | $2,124 | $7,16412 claims |
| PfizerEliquis | $19 | $6,61412 claims |
| MerckJanuvia | $101 | $6,07411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,469 hospitalist providers in California.
Other hospitalist in Lancaster
- Jennifer SchneiderSanta Rosa$1.2M
- Soham ShahBakersfield$844K
- Alpesh AminOrange$428K
- Retha GoodglickSanta Monica$156K
- Robert WachterSan Francisco$75K
- Steven WongTorrance$36K
- Edward LeeLos Angeles$30K
- Anjani KolahiOrange$30K
- Omar AldaasSan Diego$24K
- Summaiya MuhammadCastro Valley$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.